Comprehensive analysis based on DNA methylation and RNA-seq reveals hypermethylation of the up-regulated WT1 gene with potential mechanisms in PAM50 subtypes of breast cancer

Abstract

Background Breast cancer (BC), one of the most widespread cancers worldwide, caused the deaths of more than 600,000 women in 2018, accounting for about 15% of all cancer-associated deaths in women that year. In this study, we aimed to discover potential prognostic biomarkers and explore their molecular mechanisms in different BC subtypes using DNA methylation and RNA-seq. Methods We downloaded the DNA methylation datasets and the RNA expression profiles of primary tissues of the four BC molecular subtypes (luminal A, luminal B, basal-like, and HER2-enriched), as well as the survival information from The Cancer Genome Atlas (TCGA). The highly expressed and hypermethylated genes across all the four subtypes were screened. We examined the methylation sites and the downstream co-expressed genes of the selected genes and validated their prognostic value using a different dataset (GSE20685). For selected transcription factors, the downstream genes were predicted based on the Gene Transcription Regulation Database (GTRD). The tumor microenvironment was also evaluated based on the TCGA dataset. Results We found that Wilms tumor gene 1 (WT1), a transcription factor, was highly expressed and hypermethylated in all the four BC subtypes. All the WT1 methylation sites exhibited hypermethylation. The methylation levels of the TSS200 and 1stExon regions were negatively correlated with WT1 expression in two BC subtypes, while that of the gene body region was positively associated with WT1 expression in three BC subtypes. Patients with low WT1 expression had better overall survival (OS). Five genes including COL11A1, GFAP, FGF5, CD300LG, and IGFL2 were predicted as the downstream genes of WT1. Those five genes were dysregulated in the four BC subtypes. Patients with a favorable 6-gene signature (low expression of WT1 and its five predicted downstream genes) exhibited better OS than that with an unfavorable 6-gene signature. We also found a correlation between WT1 and tamoxifen using STITCH. Higher infiltration rates of CD8 T cells, plasma cells, and monocytes were found in the lower quartile WT1 group and the favorable 6-gene signature group. In conclusion, we demonstrated that WT1 is hypermethylated and up-regulated in the four BC molecular subtypes and a 6-gene signature may predict BC prognosis.

Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy

“…Cen et al found a significant decrease in proliferation of COAD cells after knocking down IGFL2-AS1 43 . In some database-based studies, IGFL2 was found as a potential pathogenic gene or gene affecting prognosis in liver, breast, renal clear cell, and bladder cancers [44][45][46][47] , which is consistent with the results of our analysis.…”

Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction

“…MYC was also found to co-amplify with PVT1 in several cancer cell lines. CD300LG has a functional dependency associated with WT1 , and upregulation and hypermethylation of WT1 have been associated with poor prognosis ( Ren et al, 2021 ). CD300LG also has a wide variety of immunological functions ( Borrego, 2013 ).…”

Unveiling Collagen’s Role in Breast Cancer: Insights into Expression Patterns, Functions and Clinical Implications

“…73 Moreover, COL11A1 is selected as the N6-methyladenosine (m6A) target gene and the downstream gene of Wilms tumor gene 1 (WT1). 74,75 Its regulation is involved in miR-29, 76 TGF-β1 signaling, 77 AKT/c/EBPβ/PDK1 axis 78 and other collagens, such as collagen type XI alpha 2 (COL11A2), collagen type XI alpha 3 (COL11A3), collagen type V alpha 1 (COL5A1) and collagen type V alpha 2 (COL5A2). Additionally, COL11A1 is observed to be upregulated in recurrent tumors, promoting tumor recurrence post chemotherapy.…”